Compared to other diabetes medications, GLP-1 drugs like Ozempic were associated with a lower risk for depression in a recent ...

For older adults with type 2 diabetes (T2D), use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with ...

A target trial emulation study compared risk for depression among older adults with type 2 diabetes initiating treatment with ...

For older adults with type 2 diabetes (T2D), use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with ...

In this target trial emulation, glucagon-like peptide-1 receptor agonists (GLP-1RAs) were associated with a lower risk of ...

The enzyme dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of glucagon-like peptide-1 (GLP-1). Since GLP-1-based therapy is a promising novel treatment of type 2 diabetes, the strategy to ...

The prevalence of type 2 diabetes is rising globally, with a disproportionate impact on individuals in low-income and middle-income countries, where access to care and new therapies is often limited.

The startling findings raise the possibility that the medicines, originally developed to treat diabetes, could one day be ...

For patients with type 2 diabetes (T2D) and chronic obstructive pulmonary disorder (COPD), sodium-glucose cotransporter-2 ...

Red ginseng extract powder significantly improved glycemic control in prediabetic Korean adults over 12 weeks without adverse ...

Learn more about whether Insmed Incorporated or Moderna, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.